Drug Trial Radar · NCT07444424
A Study to Investigate the Effect of AZD5004 on Mitiglinide and Pioglitazone in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Mar 13, 2026
Primary completion
Jul 2, 2026
Study completion Jul 2, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Mar 2, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the effect of AZD5004 on the pharmacokinetics (PK) of mitiglinide and pioglitazone in healthy participants.
Conditions
- Healthy Participants
Interventions
AZD5004Drug
AZD5004 will be administered orally.
MitiglinideDrug
Mitiglinide will be administered orally.
PioglitazoneDrug
Pioglitazone will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
- Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
- Maximum observed drug concentration (Cmax)Time frame: Part A: From Day 1 to Day 50; Part B: From Day 1 to Day 70
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Research Site
Fukuoka, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.